PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways

Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most difficult to treat cancers. Gemcitabine is still the standard of care treatment for PDAC but with modest survival benefit and well reported resistance. Here we explored potential of inhibiting p21 activated kinase 4 (PAK4), a downstream...

Descripción completa

Detalles Bibliográficos
Autores principales: Samant, Charudatt, Kale, Ramesh, Bokare, Anand, Verma, Mahip, Pai, K. Sreedhara Ranganath, Bhonde, Mandar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500449/
https://www.ncbi.nlm.nih.gov/pubmed/37720313
http://dx.doi.org/10.1016/j.bbrep.2023.101544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500449/
https://www.ncbi.nlm.nih.gov/pubmed/37720313
http://dx.doi.org/10.1016/j.bbrep.2023.101544

Ejemplares similares